Physician profile

Majid A Basit

Interventional Cardiology · Sugar Land, TX

NPI 1609078112

$56,024.98

in general payments reported to CMS, 2019-2025

31 companies · $3,684 in 2025

The $3,684 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$8,650.00
Food and Beverage$8,500.41
Travel and Lodging$3,563.28
Education$94.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $35,435.70 2019-2024 Farxiga, Brilinta, Lokelma
Medtronic Vascular, INC. $4,868.21 2019
Abbott Laboratories $4,765.06 2019-2025 Supera, Cardiomems, Aveir
Boston Scientific Corporation $2,152.02 2019-2025 Watchman Access System, Watchman Flx, Bodyguardian
Amgen INC. $2,072.12 2020-2025 Repatha, Repatha
Boehringer Ingelheim Pharmaceuticals, INC. $1,013.65 2020-2025 Jardiance
Shockwave Medical, INC $981.42 2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Sanofi-Aventis U.S. LLC $918.64 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $642.21 2019-2024 Lifevest
Novartis Pharmaceuticals Corporation $612.77 2022-2025
Actelion Pharmaceuticals US, INC. $485.37 2024-2025 Uptravi, Opsumit, Opsynvi
Abiomed $368.19 2019
Janssen Pharmaceuticals, INC $342.64 2021-2024 Xarelto
Impulse Dynamics (USA) INC. $266.28 2023-2025 Optimizer, Optimizer
Merck Sharp & Dohme LLC $236.48 2022-2024 Verquvo
Show all 31 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $156.75 2023-2025
E.R. Squibb & Sons, L.L.C. $122.83 2020-2025 Camzyos, Eliquis
Novo Nordisk INC $122.78 2022-2025 Wegovy
Biosense Webster, INC. $91.38 2025 Carto 3
Cardiovascular Systems INC. $76.57 2019-2020
Scpharmaceuticals INC. $52.20 2025
Axonics, INC. $43.99 2023-2024 Axonics
Baxter Healthcare $33.48 2024-2025 Hillrom - Carnation Ambulatory Monitor
Bayer Healthcare Pharmaceuticals INC. $27.89 2025
Phathom Pharmaceuticals, INC. $24.07 2024 Voquezna
Zoll Medical Corporation $23.35 2023
Sanofi Pasteur INC. $21.10 2024
Irhythm Technologies, INC. $19.25 2024 Zio Xt Patch, Zio Monitor
Zoll Circulation INC $17.88 2023 Temperature Management System, Temperature Management System Start-Up Kit, Catheter
Preventice Services, LLC $15.55 2021
Lexicon Pharmaceuticals, INC. $15.15 2023 Inpefa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Majid A Basit

$56,024.98

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $3,684 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/72244/majid-a-basit

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.